207 related articles for article (PubMed ID: 33249990)
1. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Amare GG; Meharie BG; Belayneh YM
J Oncol Pharm Pract; 2021 Apr; 27(3):673-678. PubMed ID: 33249990
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.
Kumar N; Sharma U; Singh C; Singh B
Curr Top Med Chem; 2012; 12(13):1436-55. PubMed ID: 22650376
[TBL] [Abstract][Full Text] [Related]
3. The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.
Knobloch J; Jungck D; Koch A
Curr Mol Med; 2017; 17(2):108-117. PubMed ID: 28429672
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: a review of approved and investigational uses.
Matthews SJ; McCoy C
Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
[TBL] [Abstract][Full Text] [Related]
5. Theoretical basis for the activity of thalidomide.
Meierhofer C; Dunzendorfer S; Wiedermann CJ
BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the mystery of thalidomide teratogenicity.
Ito T; Handa H
Congenit Anom (Kyoto); 2012 Mar; 52(1):1-7. PubMed ID: 22348778
[TBL] [Abstract][Full Text] [Related]
7. The promise of thalidomide: evolving indications.
Joglekar S; Levin M
Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide in cutaneous lupus erythematosus.
Pelle MT; Werth VP
Am J Clin Dermatol; 2003; 4(6):379-87. PubMed ID: 12762830
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide use in the US : experience with pregnancy testing in the S.T.E.P.S. programme.
Uhl K; Cox E; Rogan R; Zeldis JB; Hixon D; Furlong LA; Singer S; Holliman T; Beyer J; Woolever W
Drug Saf; 2006; 29(4):321-9. PubMed ID: 16569081
[TBL] [Abstract][Full Text] [Related]
11. Management of thalidomide toxicity.
Ghobrial IM; Rajkumar SV
J Support Oncol; 2003; 1(3):194-205. PubMed ID: 15334875
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
13. [Thalidomide--a dreaded drug with new indications].
Waage A; Seidel C
Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2954-7. PubMed ID: 11715779
[TBL] [Abstract][Full Text] [Related]
14. [Action mechanism of thalidomide in treatment of multiple myeloma].
Tsukagoshi S
Nihon Rinsho; 2007 Dec; 65(12):2291-5. PubMed ID: 18069275
[TBL] [Abstract][Full Text] [Related]
15. [The revival of thalidomide: an old drug with new indications].
Laffitte E
Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide: rationale for renewed use in immunological disorders.
Schuler U; Ehninger G
Drug Saf; 1995 Jun; 12(6):364-9. PubMed ID: 8527011
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide: emerging role in cancer medicine.
Richardson P; Hideshima T; Anderson K
Annu Rev Med; 2002; 53():629-57. PubMed ID: 11818493
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide for erythema nodosum leprosum and other applications.
Okafor MC
Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
[TBL] [Abstract][Full Text] [Related]
20. The return of thalidomide: can birth defects be prevented?
Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA
Drug Saf; 1999 Sep; 21(3):161-9. PubMed ID: 10487395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
